-
CD25+FOXP3+CD45RA- Treg Cells and Cancer Prognosis(Post)
The Role of CD25+FOXP3+CD45RA- Treg Cells in Cancer PrognosisIntroductionRegulatory T-cells (Treg cells) are a specialized subset of T-cells that play a pivotal role in maintaining immune homeostasis
The Neural Shield: How Cancer-Induced Nerve Injury Drives Immunotherapy Resistance(Post)For years, our understanding of cancer focused primarily on the tumor cells themselves and the immune system's response. However, a groundbreaking wave of research is revealing a startling truth: ner
Western Blot Dictionary - Mandarin(Page)蛋白质印迹词典(Western Blot 常用术语,中文) | Assay Genie
Gemtuzumab: Advancing CD33-Targeted Therapies in AML Research(Post)Key Facts About GemtuzumabWhat is Gemtuzumab?Gemtuzumab is an antibody-drug conjugate (ADC) targeting CD33, a protein expressed on the surface of myeloid cells. It is widely recognized f
Ifabotuzumab: Exploring the Role of Anti-EphA3 in Cancer Research(Post)What You Need to Know About IfabotuzumabWhat is Ifabotuzumab?Ifabotuzumab is a monoclonal antibody targeting EphA3, a receptor tyrosine kinase overexpressed in certain cancers. It plays
Siltuximab: Exploring IL-6 Inhibition in Castleman’s Disease and Research(Post)Quick Facts About SiltuximabWhat is Siltuximab?Siltuximab is a monoclonal antibody targeting interleukin-6 (IL-6), a cytokine involved in inflammation and immune regulation.What is the m
Sweet Deception: How a New Antibody Therapy Unmasks Pancreatic Cancer(Post)Sweet Deception: How a New Antibody Therapy Unmasks Pancreatic Cancer Sweet Deception: How a New Antibody Therapy Unmasks Pancreatic Cancer Pancreatic canc
A New Dawn in Lupus Treatment: The Promise of Topical RNA Therapeutics(Post)A New Dawn in Lupus Treatment: The Promise of Topical RNA Therapeutics Systemic Lupus Erythematosus (SLE) is a debilitating autoimmune disease that has long puzzled researchers and clinicians. Howeve
Brentuximab: Unveiling the Role of Anti-CD30 in Cancer Research(Post)Key Facts About BrentuximabWhat is Brentuximab?Brentuximab is a monoclonal antibody targeting CD30, commonly used in the treatment of Hodgkin lymphoma and systemic anaplastic large cell
Ipilimumab and Nivolumab: Advancing Research on CTLA-4 in Cancer Therapy(Post)What You Need to Know About IpilimumabWhat is Ipilimumab?Ipilimumab is a monoclonal antibody that targets CTLA-4, a protein involved in downregulating the immune system, to boost the bod
Erenumab: Transforming Migraine Prevention Through CGRP Receptor Inhibition(Post)Quick Facts About ErenumabWhat is Erenumab?Erenumab is a fully human monoclonal antibody designed to prevent migraines by targeting the calcitonin gene-related peptide (CGRP) receptor.
Anti-Tag Antibodies(Page) Bersanlimab: Revolutionizing Cancer Research with Anti-CD47 Therapeutics(Post)What You Need to Know About BersanlimabWhat is Bersanlimab?Bersanlimab is a cutting-edge anti-CD47 monoclonal antibody designed to disrupt cancer cells' evasion of immune detection.What
Enokizumab: Exploring Its Mechanism, Clinical Applications, and Biosimilar Advancements(Post)Quick Facts About EnokizumabWhat is Enokizumab?Enokizumab is a monoclonal antibody designed to target interleukin-9 (IL-9), a cytokine involved in inflammatory responses. It has been stu
Metabolic Bloodhounds: Engineering Immune Cells to Track Cancer's Chemical Trail(Post)Imagine a specialized squad of immune cells, meticulously trained and equipped, not just to fight cancer, but to sniff it out by its unique metabolic scent. This isn't science fiction; it's the groun
Onvatilimab: Redefining the Role of Anti-CD47 in Cancer Research(Post)Quick Facts About OnvatilimabWhat is Onvatilimab?Onvatilimab is a monoclonal antibody targeting CD47, often referred to as the "don't eat me" signal, which is overexpressed on many cance
Lacnotuzumab: Unveiling the Role of Anti-CD47 in Cancer Research(Post)Quick Facts About LacnotuzumabWhat is Lacnotuzumab?Lacnotuzumab is a monoclonal antibody targeting CD47, a protein that helps cancer cells evade immune system destruction.What is the mec
TIM-3/Gal-9 Pathway in Antiparasitic Immunity(Post)Exploring the Role of TIM-3/Gal-9 in Antiparasitic ImmunityIntroductionThe immune system is a complex network of cells and molecules that work together to defend the body against pathogens, including
Iscalimab: Advancing Research in Autoimmune Diseases and Transplantation(Post)What You Need to Know About IscalimabWhat is Iscalimab?Iscalimab (CFZ533) is a monoclonal antibody targeting CD40, a key protein involved in immune system regulation.What is the mechanis
Belimumab: Unveiling Its Role in Lupus and Beyond(Post)Quick Facts About BelimumabWhat is Belimumab?Belimumab is a monoclonal antibody used to treat systemic lupus erythematosus (SLE), an autoimmune disease. It is marketed under the brand na
Naratuximab: Redefining Cancer Therapy with Precision Medicine(Post)Quick Facts About NaratuximabWhat is Naratuximab?Naratuximab is an anti-CD37 monoclonal antibody-drug conjugate (ADC) designed to target B-cell malignancies, particularly non-Hodgkin lym
Unveiling Prezalumab: Targeting the Role of Anti-CD47 in Cancer Immunotherapy(Post)What You Need to Know About PrezalumabWhat is Prezalumab?Prezalumab is a monoclonal antibody designed to target CD47, a protein often overexpressed in cancer cells to evade immune detect
인터루킨 8 시그널링(Page) Tocilizumab: Advancing Therapeutics and Research with Biosimilars(Post)What You Need to Know About TocilizumabWhat is Tocilizumab?Tocilizumab is a monoclonal antibody that targets the interleukin-6 (IL-6) receptor, widely used for managing autoimmune and in
Relatlimab: Unlocking the Potential of LAG-3 Inhibition in Cancer Research(Post)Quick Facts About RelatlimabWhat is Relatlimab?Relatlimab is a monoclonal antibody that targets LAG-3 (Lymphocyte Activation Gene-3), a key immune checkpoint involved in T-cell regulatio
Zolbetuximab: A Breakthrough in Targeting Claudin 18.2 for Cancer Treatment(Post)Quick Facts About ZolbetuximabWhat is Zolbetuximab?Zolbetuximab is a monoclonal antibody that targets Claudin 18.2, a protein overexpressed in gastric and pancreatic cancers, enhancing t
Imalumab: Unveiling Its Mechanism, Clinical Potential, and Biosimilar Advancements(Post)What You Need to Know About ImalumabWhat is Imalumab?Imalumab is a monoclonal antibody targeting macrophage migration inhibitory factor (MIF), a key regulator of inflammation and immune
Narnatumab: Unveiling the Role of Anti-CD47 in Cancer Research(Post)Quick Facts About NarnatumabWhat is Narnatumab?Narnatumab is a monoclonal antibody targeting CD47, a key immune checkpoint that helps cancer cells evade destruction by the immune system.
Milatuzumab: Unveiling Its Role in Cancer Immunotherapy and Research(Post)What You Need to Know About MilatuzumabWhat is Milatuzumab?Milatuzumab is a humanized monoclonal antibody targeting CD74, a molecule involved in antigen presentation and cell signaling.W
Murlentamab: Revolutionizing Cancer Research with Targeted Therapy(Post)Quick Facts About MurlentamabWhat is Murlentamab?Murlentamab is a novel monoclonal antibody designed to target CD47, a "don’t eat me" signal that helps cancer cells evade the immune syst
Labetuzumab: Revolutionizing Cancer Research with Targeted Therapies(Post)Quick Facts About LabetuzumabWhat is Labetuzumab?Labetuzumab is a monoclonal antibody targeting CEACAM5, a protein overexpressed in various cancers, primarily colorectal carcinoma.How do
Tinurilimab: Advancing Immunotherapy Through CD47 Blockade(Post)Quick Facts About TinurilimabWhat is Tinurilimab?Tinurilimab is a monoclonal antibody targeting CD47, a protein that cancer cells use to evade immune system attack. By blocking CD47, Tin
Tomaralimab: Unveiling the Role of Anti-CD47 in Cancer Research(Post)Quick Facts About TomaralimabWhat is Tomaralimab?Tomaralimab is an anti-CD47 monoclonal antibody designed to enhance immune system recognition of cancer cells by blocking the "don't eat
Ulviprubart: A Breakthrough in Autoimmune Disease Treatment(Post)Quick Facts About UlviprubartWhat is Ulviprubart?Ulviprubart is an experimental complement inhibitor designed to modulate immune responses in autoimmune diseases.What is the mechanism of
Neuroinflammation and Compulsive Behavior: The Role of Astrocytes in OCD(Post)Imagine a mind trapped in a loop, endlessly repeating actions or thoughts, driven by an invisible force. For millions worldwide, this is the reality of Obsessive-Compulsive Disorder (OCD). While trad
ELISA Troubleshooting: When Standards Read Below the Blank(Post)Quick answer On the GDF-6 (Growth Differentiation Factor 6) ELISA Kit, a researcher saw an elevated blank (OD ≈ 0.41) with the two lowest standards reading at or below it, and no signa
Questions About Dilutions? A Real Example of How to Prepare Your ELISA Solutions(Post)Quick answer A researcher preparing a Human IL-18 ELISA wasn't sure whether the protocol's “300-fold” HRP-Streptavidin step meant adding 40 µL of concentra
Enapotamab: Advancing Cancer Research with Innovative Therapeutics(Post)Quick Facts About EnapotamabWhat is Enapotamab?Enapotamab is an experimental antibody-drug conjugate (ADC) developed to target tumor cells selectively, offering new hope in cancer treatm
Ruplizumab: Unveiling the Role of Anti-CD47 in Cancer Research(Post)Quick Facts About RuplizumabWhat is Ruplizumab?Ruplizumab is an investigational monoclonal antibody designed to target CD47, a protein that helps cancer cells evade immune detection.What
Lusvertikimab: Unveiling the Potential in Immuno-Oncology(Post)What You Need to Know About LusvertikimabWhat is Lusvertikimab?Lusvertikimab is a monoclonal antibody designed to inhibit the IL-4 receptor, a key player in regulating immune responses,
Enfortumab Vedotin: Unveiling Its Role in Cancer Treatment and the Rise of Biosimilars(Post)Quick Facts About EnfortumabWhat is Enfortumab Vedotin?Enfortumab vedotin is an innovative cancer therapy, primarily used in treating urothelial carcinoma (bladder cancer) that has not r
Uliledlimab: Unveiling the Role of Anti-CD47 in Cancer Research(Post)Quick Facts About UliledlimabWhat is Uliledlimab?Uliledlimab is a monoclonal antibody targeting CD47, a checkpoint protein that helps tumors evade immune system detection. By blocking CD
Sirexatamab: Advancing CD47-Targeted Cancer Therapy and Research(Post)Quick Facts About SirexatamabWhat is Sirexatamab?Sirexatamab is an investigational monoclonal antibody designed to target CD47, a key immune checkpoint involved in cancer evasion.How Doe
Apamistamab: Advancing Leukemia Treatment through Targeted Radioimmunotherapy(Post)Quick Facts About ApamistamabWhat is Apamistamab?Apamistamab is a monoclonal antibody that targets the CD45 antigen on hematopoietic cells.How does Apamistamab work?When labeled with the
Unlocking the Next Wave of Cancer Treatment: The Promise and Progress of CAR-T Cell Therapy(Post)Imagine a living drug, engineered from a patient's own immune system, that can hunt down and destroy cancer cells with remarkable precision. This isn't science fiction; it's the reality of Chimeric An
In Vivo CAR-T Engineering: The Dawn of Off-the-Shelf Immunotherapy(Post)Imagine a future where cancer treatment isn't a grueling, months-long process involving cell extraction and reinfusion, but a simple, targeted injection that reprograms your body's own immune cells t
The Bioelectronic Revolution: How Vagus Nerve Stimulation is Redefining Autoimmune Therapy in 2026(Post)Imagine a future where chronic autoimmune diseases, once managed by powerful pharmaceuticals with challenging side effects, are instead calmed by a gentle electrical pulse. This isn't science fiction
Troubleshooting high ELISA concentrations(Post)QUICK ANSWER If your ELISA returns sample concentrations that are orders of magnitude too high, the assay itself is usually fine — the error is almost always in data analysis. The most
Immunohistochemistry Protocol Guide - Mandarin(Page)免疫组织化学规程指南(IHC,中文) | Assay Genie
Lemzoparlimab: Targeting CD47 for Cancer Immunotherapy Advancements(Post)Quick Facts About LemzoparlimabWhat is Lemzoparlimab?Lemzoparlimab is a monoclonal antibody that targets CD47, a protein known for its role in helping tumors evade the immune system. By
Alsevalimab: Targeting CD47 for Cancer Research and Treatment(Post)Quick Facts About AlsevalimabWhat is Alsevalimab?Alsevalimab is a monoclonal antibody targeting CD47, a protein involved in immune evasion by cancer cells. By blocking CD47, Alsevalimab
Nadecnemab: Advancing Cancer Research Through Anti-CD47 Targeting(Post)Quick Facts About NadecnemabWhat is Nadecnemab?Nadecnemab is an investigational monoclonal antibody that targets CD47, a key immune checkpoint protein involved in cancer evasion.How Does
Lorvotuzumab: Targeting CD56 in Cancer Research and Therapeutic Development(Post)Quick Facts About LorvotuzumabWhat is Lorvotuzumab?Lorvotuzumab is an antibody-drug conjugate (ADC) designed to target CD56, a surface antigen commonly overexpressed in neuroendocrine tu
Pamrevlumab: Unveiling the Potential of Anti-Fibrotic Therapy in Clinical Trials and Research(Post)Quick Facts About PamrevlumabWhat is Pamrevlumab?Pamrevlumab (FG-3019) is a monoclonal antibody designed to target and inhibit the connective tissue growth factor (CTGF), a key driver of